Herantis Pharma’s financial calendar and annual general meeting for 2023
Herantis Pharma Plc
Company release 15 Dec 2022 at 9:00 am EET
Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease-modifying therapies for Parkinson’s disease, hereby publishes the financial calendar for 2023.
Financial year 2022:
|
Quiet period before 2H and FY 2022 report |
February 1 – March 2, 2023 |
|
2H and FY 2022 report |
March 2, 2023 |
|
Annual report 2022 |
March 28, 2023 |
Financial year 2023:
|
Deadline for submission of proposal for AGM |
February 20, 2023 |
|
Annual General Meeting (AGM) |
April 20, 2023 |
|
Quiet period before 1H 2023 report |
July 23 – August 24, 2023 |
|
1H 2023 report |
August 24, 2023 |
The dates are subject to change.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the ability to be delivered to the brain via subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com.
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com